The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis

Journal of Neuro-Oncology

Volumn 106, Issue 1, 2012, Pages 81-88

  Brastianos, Priscilla K ^a,b   Brastianos, Harry C ^c,d   Hsu, Wesley ^c   Sciubba, Daniel M ^c   Kosztowski, Thomas ^c   Tyler, Betty M ^c   Recinos, Violette Renard ^c   Burger, Peter ^e   Grossman, Stuart A ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinomatous meningitis; Intrathecal bevacizumab; Leptomeningeal carcinomatosis; Neoplastic meningitis; Rabbit model of leptomeningeal carcinomatosis

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CONTROLLED STUDY; MALE; NEUROTOXICITY; NONHUMAN; RABBIT; SINGLE DRUG DOSE;

ANESTHESIA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CISTERNA MAGNA; INJECTIONS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; KAPLAN-MEIER ESTIMATE; MALE; MENINGEAL CARCINOMATOSIS; NEUROTOXICITY SYNDROMES; RABBITS; SURVIVAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83055173018     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0655-9     Document Type: Article

References (51)

1. SA Grossman MJ Krabak 1999 Leptomeningeal carcinomatosis Cancer Treat Rev 25 2 103 119 10395835 10.1053/ctrv.1999.0119 1:STN:280:DyaK1Mzis1Cmuw%3D%3D (Pubitemid 29353669)
2. MC Chamberlain 2006 Neoplastic meningitis Neurologist 12 4 179 187 16832237 10.1097/01.nrl.0000219732.33321.cc (Pubitemid 44134044)
3. NCCN Clinical Practice Guidelines in Oncology (2011). 34-40
4. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1182 1186 4938153 10.1056/NEJM197111182852108 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
5. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 10 795 803 12360282 10.1038/nrc909 1:CAS:528:DC%2BD38XnsVGrtbk%3D (Pubitemid 37328914)
6. RS Kerbel 2008 Tumor angiogenesis N Engl J Med 358 19 2039 2049 18463380 10.1056/NEJMra0706596 1:CAS:528:DC%2BD1cXlsFyrtro%3D (Pubitemid 351656458)
7. G Ranieri R Patruno E Ruggieri S Montemurro P Valerio D Ribatti 2006 Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Curr Med Chem 13 16 1845 1857 16842197 10.2174/092986706777585059 1:CAS:528:DC%2BD28Xms1CltrY%3D
8. JC Reijneveld MJ Taphoorn OA Kerckhaert TA Drixler W Boogerd EE Voest 2003 Angiostatin prolongs the survival of mice with leptomeningeal metastases Eur J Clin Invest 33 1 76 81 12492456 10.1046/j.1365-2362.2003.01056.x 1:CAS:528:DC%2BD3sXht1Wqurk%3D (Pubitemid 36051295)
9. G Stockhammer W Poewe S Burgstaller F Deisenhammer A Muigg S Kiechl E Schmutzhard H Maier S Felber P Schumacher E Gunsilius G Gastl 2000 Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis Neurology 54 8 1670 1676 10762512 1:CAS:528:DC%2BD3cXjtF2ltL0%3D
10. J Mordenti K Thomsen V Licko L Berleau JW Kahn RA Cuthbertson ET Duenas AM Ryan C Schofield TW Berger YG Meng J Cleland 1999 Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation Toxicol Sci 52 1 101 106 10568703 10.1093/toxsci/52.1.101 1:CAS:528: DyaK1MXns1egtr0%3D
11. J Mordenti RA Cuthbertson N Ferrara K Thomsen L Berleau V Licko PC Allen CR Valverde YG Meng DT Fei KM Fourre AM Ryan 1999 Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration Toxicol Pathol 27 5 536 544 10528633 10.1177/019262339902700507 1:CAS:528:DyaK1MXmsFyntLo%3D (Pubitemid 29446822)
12. J Mordenti K Thomsen V Licko H Chen YG Meng N Ferrara 1999 Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans Toxicol Pathol 27 1 14 21 10367667 10.1177/019262339902700104 1:CAS:528:DyaK1MXhtlSit70%3D (Pubitemid 29075738)
13. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
14. RF Spaide YL Fisher 2006 Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina 26 3 275 278 16508426 10.1097/00006982-200603000-00004 (Pubitemid 44318179)
15. SJ Bakri MR Snyder JM Reid JS Pulido MK Ezzat RJ Singh 2007 Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 12 2179 2182 18054637 10.1016/j.ophtha.2007.09.012 (Pubitemid 350181137)
16. JA Frank M Girton AJ Dwyer DC Wright PJ Cohen JL Doppman 1988 Meningeal carcinomatosis in the VX2 rabbit tumor model: detection with Gd-DTPA-enhanced MR imaging Radiology 167 3 825 829 3363148 1:STN:280:DyaL1c3gsVWrsg%3D%3D
17. PC Phillips TT Than LC Cork J Hilton BS Carson OM Colvin LB Grochow 1992 Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis Cancer Res 52 22 6168 6174 1423260 1:CAS:528:DyaK3sXktlU%3D
18. M van der Flier FE Coenjaerts PN Mwinzi E Rijkers M Ruyken J Scharringa JL Kimpen AI Hoepelman SP Geelen 2005 Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis J Neuroimmunol 160 1-2 170 177 15710470 10.1016/j.jneuroim.2004.11.013 (Pubitemid 40248606)
19. L Feiner EE Barr YB Shui NM Holekamp MA Brantley Jr 2006 Safety of intravitreal injection of bevacizumab in rabbit eyes Retina 26 8 882 888 10.1097/01.iae.0000230717.85319.f5 17031287 10.1097/01.iae.0000230717.85319.f5 (Pubitemid 44547440)
20. RP Manzano GA Peyman P Khan M Kivilcim 2006 Testing intravitreal toxicity of bevacizumab (Avastin) Retina 26 3 257 261 16508423 10.1097/00006982- 200603000-00001 (Pubitemid 44318176)
21. WJ Kim HO Jeong SK Chung 2010 The effect of bevacizumab on corneal neovascularization in rabbits Korean J Ophthalmol 24 4 230 236 10.3341/kjo.2010.24.4.230 20714387 10.3341/kjo.2010.24.4.230 1:CAS:528:DC%2BC3MXht1GktbjP
22. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (3):363-372 e365. doi: 10.1016/j.ophtha.2005.11. 019
23. ZF Bashshur A Bazarbachi A Schakal ZA Haddad CP El Haibi BN Noureddin 2006 Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 142 1 1 9 10.1016/j.ajo.2006.02.037 16815245 10.1016/j.ajo.2006.02.037 1:CAS:528:DC%2BD28Xms1GktLg%3D (Pubitemid 43946791)
24. L Amselem E Cervera M Diaz-Llopis J Montero M Garcia-Pous P Udaondo S Garcia-Delpech D Salom 2007 Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up Eye 21 4 566 567 10.1038/sj.eye.6702647 17128202 1:STN:280:DC%2BD2s3gsFWgsw%3D%3D (Pubitemid 46564160)
25. RG Pullen 1985 Effect of ventricular tonicity upon cerebrospinal fluid production in rabbits J Physiol 362 273 283 4020689 1:STN:280: DyaL2M3msVeqtQ%3D%3D (Pubitemid 15122247)
26. MA Samphilipo Jr SJ Hassenbusch LB Grochow FL Starr 3rd JH Anderson 1987 A reservoir model for repeated CSF access in the rabbit J Neurosci Methods 22 1 47 52 3695567 10.1016/0165-0270(87)90088-4 (Pubitemid 17146851)
27. R Langer J Folkman 1976 Polymers for the sustained release of proteins and other macromolecules Nature 263 5580 797 800 995197 10.1038/263797a0 1:CAS:528:DyaE2sXnvVKntQ%3D%3D
28. E Georges F Breitburd N Jibard G Orth 1985 Two Shope papillomavirus- associated VX2 carcinoma cell lines with different levels of keratinocyte differentiation and transplantability J Virol 55 1 246 250 2409299 1:CAS:528:DyaL2MXksFWisrc%3D (Pubitemid 15048713)
29. YS Lin C Nguyen JL Mendoza E Escandon D Fei YG Meng NB Modi 1999 Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor J Pharmacol Exp Ther 288 1 371 378 9862791 1:CAS:528:DyaK1MXisV2jtg%3D%3D (Pubitemid 29113511)
30. HP Gerber N Ferrara 2005 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 3 671 680 15705858 1:CAS:528:DC%2BD2MXhtVWnsb0%3D (Pubitemid 40216420)
31. SB Wedam JA Low SX Yang CK Chow P Choyke D Danforth SM Hewitt A Berman SM Steinberg DJ Liewehr J Plehn A Doshi D Thomasson N McCarthy H Koeppen M Sherman J Zujewski K Camphausen H Chen SM Swain 2006 Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 5 769 777 16391297 10.1200/JCO.2005.03.4645 1:CAS:528:DC%2BD28XitVGisbY%3D (Pubitemid 46622044)
32. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
33. RM Rich PJ Rosenfeld CA Puliafito SR Dubovy JL Davis HW Flynn Jr S Gonzalez WJ Feuer RC Lin GA Lalwani JK Nguyen G Kumar 2006 Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 5 495 511 16770255 10.1097/01.iae.0000225766. 75009.3a (Pubitemid 44620390)
34. SD Zondor PJ Medina 2004 Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies Ann Pharmacother 38 7-8 1258 1264 15187215 1:CAS:528:DC%2BD2cXlvFems70%3D (Pubitemid 38802172)
35. JJ Vredenburgh A Desjardins JE Herndon 2nd J Marcello DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan J Sampson M Wagner L Bailey DD Bigner AH Friedman HS Friedman 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 30 4722 4729 17947719 10.1200/JCO.2007.12.2440 1:CAS:528:DC%2BD2sXhtlCgsLjF (Pubitemid 350086473)
36. JJ Vredenburgh A Desjardins JE Herndon 2nd JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 4 1253 1259 17317837 10.1158/1078-0432.CCR-06-2309 1:CAS:528:DC%2BD2sXhvF2htr8%3D (Pubitemid 46424067)
37. MS Gordon D Cunningham 2005 Managing patients treated with bevacizumab combination therapy Oncology 69 Suppl 3 25 33 16301833 10.1159/000088481 1:CAS:528:DC%2BD2MXht1aqsrbP (Pubitemid 41680950)
38. RA Costa R Jorge D Calucci JA Cardillo LA Melo Jr IU Scott 2006 Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study Investg Ophthalmol Vis Sci 47 10 4569 4578 10.1167/iovs.06-0433 (Pubitemid 46579387)
39. TU Krohne N Eter FG Holz CH Meyer 2008 Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am J Ophthalmol 146 4 508 512 18635152 10.1016/j.ajo.2008.05.036 1:CAS:528:DC%2BD1cXhtFektbfP
40. Li K, Zhang G, Zhao J, Wang X, Li Y, Hu Y (2010) Vascular endothelial growth factor antisense oligonucleotides inhibit leptomeningeal metastasis in vivo. Med Oncol. 1-7. doi: 10.1007/s12032-010-9580-6
41. UU Inan B Avci T Kusbeci B Kaderli R Avci SG Temel 2007 Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes Investg Ophthalmol Vis Sci 48 4 1773 1781 10.1167/iovs.06-0828 (Pubitemid 351261365)
42. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 9 987 989 11533692 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D (Pubitemid 32937367)
43. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 5706 58 62 15637262 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar (Pubitemid 40093472)
44. RT Tong Y Boucher SV Kozin F Winkler DJ Hicklin RK Jain 2004 Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 11 3731 3736 15172975 10.1158/0008-5472.CAN-04-0074 1:CAS:528:DC%2BD2cXksVKgur8%3D (Pubitemid 38697278)
45. F Winkler SV Kozin RT Tong SS Chae MF Booth I Garkavtsev L Xu DJ Hicklin D Fukumura E di Tomaso LL Munn RK Jain 2004 Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 6 553 563 15607960 1:CAS:528:DC%2BD2MXktVantw%3D%3D (Pubitemid 40017699)
46. CG Willett Y Boucher E di Tomaso DG Duda LL Munn RT Tong DC Chung DV Sahani SP Kalva SV Kozin M Mino KS Cohen DT Scadden AC Hartford AJ Fischman JW Clark DP Ryan AX Zhu LS Blaszkowsky HX Chen PC Shellito GY Lauwers RK Jain 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2 145 147 10.1038/nm988 14745444 10.1038/nm988 1:CAS:528:DC%2BD2cXoslKmtQ%3D%3D (Pubitemid 38524883)
47. CG Willett Y Boucher DG Duda E di Tomaso LL Munn RT Tong SV Kozin L Petit RK Jain DC Chung DV Sahani SP Kalva KS Cohen DT Scadden AJ Fischman JW Clark DP Ryan AX Zhu LS Blaszkowsky PC Shellito M Mino-Kenudson GY Lauwers 2005 Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J Clin Oncol: Off J Am Soc Clin Oncol 23 31 8136 8139 10.1200/JCO.2005.02.5635 10.1200/JCO.2005.02.5635 (Pubitemid 46657433)
48. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol Off J Am Soc Clin Oncol 21 1 60 65 10.1200/JCO.2003.10.066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D
49. VA Levin HD Landahl 1985 Pharmacokinetic approaches to drug distribution in the cerebrospinal fluid based on ventricular administration in beagle dogs J Pharmacokinet Biopharm 13 4 387 403 3936919 10.1007/BF01061476 1:CAS:528:DyaL28XmtFCqtQ%3D%3D (Pubitemid 16207486)
50. DW Laske KM Muraszko EH Oldfield HL DeVroom C Sung RL Dedrick TR Simon J Colandrea C Copeland D Katz L Greenfield ES Groves LL Houston RJ Youle 1997 Intraventricular immunotoxin therapy for leptomeningeal neoplasia Neurosurgery 41 5 1039 1049 9361057 10.1097/00006123-199711000-00005 1:STN:280: DyaK1c%2Fis12isw%3D%3D discussion 1049-1051 (Pubitemid 27475464)
51. K Kramer NK Cheung J Humm G DiResta E Arbit S Larson R Finn M Rosenblum H Nguyen G Gonzalez C Liu YF Yang ME Mendelsohn AP Gillio 1997 Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates J Neurooncol 35 2 101 111 9266446 10.1023/A:1005822524905 1:STN:280:DyaK2svhtFClug%3D%3D (Pubitemid 27361678)